Autopsy report · NCT04933968
Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
Cause of deathFunding or business
“Strategic sponsor decision”
Life of this trial
- Registered 9 months before it started.
- Ran for about 1 year 10 months before it stopped.
- 17 participants enrolled.
- Results were posted on the registry 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- AlloVir
- Sponsor type
- Industry
- Conditions
- Respiratory Tract Viral Infections; Human Metapneumovirus (hMPV) Infection; Parainfluenza (PIV) Infection; Respiratory Syncytial Viral (RSV) Infection; Influenza Infection
- Interventions
- ALVR106; Placebo
- Participants
- 17
- Sites
- 21
- Countries
- United States
Trials that died the same way
- Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
“Strategic decision of Sponsor” - Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
“Sponsor's strategic decision” - Study on Safety and Performance of Medtentia Mitral Valve Repair System in Surgical Repair of Mitral Regurgitation
“Strategic decision by Sponsor” - Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
“Sponsor decision due to strategic considerations” - A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
“Sponsor's strategic business decision”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.